Itacitinib in Advanced Hepatocellular Carcinoma

Summary

This research will assess the effects of Itacitinib as a second line treatment for patients with advanced inflammatory hepatocellular carcinoma (HCC), a type of liver cancer. Itacinib is a protein inhibitor of the tyrosine kinase, JAK1, which is believed to enable cancer cells to metastasise to other parts of the body.

Timeline

Start

2018-12-03

Primary completion

2023-04-07

Completion

2023-04-07

Publications

• Background Troiani A, Martinez M, Ward C, Benartzi CW, Pinato DJ, Sharma R. Safety and efficacy of itacitinib, a selective JAK1 inhibitor, in advanced hepatocellular cancer: Phase 1b trial (JAKAL). Future Oncol. 2024;20(36):2839-2847. doi: 10.1080/14796694.2024.2396795. Epub 2024 Sep 16.

Drugs

Indications